Both tumor markers, HER1 and HER2, are specifically recognized by the chimeric/humanized monoclonal antibodies, Erbitux (Cetuximab) and Herceptin (Trastuzumab) which are approved for therapy of colorectal carcinoma and breast cancer, respectively. Here, EGFR is linked to neoplasm.